Cybin Inc (CYBN)

$6.18 +0.15 (2.49%)
Market Cap 155.66M
Revenue (ttm) 0.00
Net Income (ttm) -81.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 434,600
Avg Vol 858,448
Day's Range N/A - N/A
Shares Out 25.19M
Stochastic %K 85%
Beta 0.66
Analysts Strong Sell
Price Target $43.20

Company Profile

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical...

Industry: Biotechnology
Sector: Healthcare
Website: cybin.com
Address:
100 King Street West, Suite 5600, Toronto, Canada
BelieveinthePK
BelieveinthePK Nov. 29 at 4:00 PM
$CYBN Compass is going for a tx resistant depression indication whereas CYBN is pursuing a major depression indication (plus generalized anxiety reason for use with a non-psilocybin based molecule). CYBN has favorable pharmacokinetics because it uses deuterated psilocin which bypasses liver metabolism unlike compass’s psilocybin drug. VA probably chose Compass because of the indication and because they are a little further along with their phase 3 trial.
0 · Reply
Hanaleimike
Hanaleimike Nov. 28 at 8:07 PM
$CYBN so cybn vs compass. I’m invested in atai. I read today about the VA investment in a phase 3 with compass. Can someone explain the main differences between these two companies and why the VA would choose compass over cybin?
1 · Reply
Mastacash
Mastacash Nov. 27 at 5:08 PM
$CYBN I mean it would explain a lot with this stock, it has trading bizarre for 5 years. Get the f*ck of the neo exchange, what a cesspool Canada is. https://www.ctvnews.ca/business/article/market-manipulation-cases-trending-up-in-canada-regulator-data/
1 · Reply
outlawinvestor1
outlawinvestor1 Nov. 26 at 8:37 PM
$CYBN bought more today. updated outstanding shares after October financing ~50 million. company has ~$220M net cash after paying off debt. biotech funds bought for $6.50/sh. still a great deal below $6 imho. i assume price will start to rise as 2026 readouts approach.
0 · Reply
starbucks_cups_with_rum
starbucks_cups_with_rum Nov. 26 at 4:12 PM
$CYBN I will buy back in next year
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 26 at 2:19 AM
Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.15 - $0.25 Exit Price Target: $0.47 Profit Margin: +90% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
BankOnTheFuture
BankOnTheFuture Nov. 25 at 8:43 PM
$CMPS $ATAI $CYBN $MNMD
0 · Reply
CMontgomeryBurns
CMontgomeryBurns Nov. 25 at 8:36 PM
$CYBN NJ leading the way https://newjerseymonitor.com/2025/11/25/nj-bill-legalize-psychedelic-mushrooms/
0 · Reply
Rico_Again_Jorge
Rico_Again_Jorge Nov. 25 at 8:30 PM
$CYBN Do not try to be too smart in this place
0 · Reply
Rico_Again_Jorge
Rico_Again_Jorge Nov. 25 at 8:29 PM
$CYBN Just yourself
0 · Reply
Latest News on CYBN
Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 3:11 PM EST - 16 days ago

Cybin Inc. (CYBN) Q2 2026 Earnings Call Transcript

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Nov 13, 2025, 7:20 AM EST - 16 days ago

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Nov 12, 2025, 7:30 AM EST - 17 days ago

Cybin to Participate in the Jefferies Global Healthcare Conference in London

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Nov 6, 2025, 7:30 AM EST - 23 days ago

Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 5, 2025, 7:30 AM EST - 24 days ago

Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Nov 3, 2025, 7:30 AM EST - 26 days ago

Cybin to Participate at the 2025 Milken Institute Future of Health Summit

Cybin Announces Closing of $175 Million Registered Direct Offering

Oct 31, 2025, 4:19 PM EDT - 4 weeks ago

Cybin Announces Closing of $175 Million Registered Direct Offering

Cybin Announces $175 Million Registered Direct Offering

Oct 28, 2025, 8:00 AM EDT - 4 weeks ago

Cybin Announces $175 Million Registered Direct Offering

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Oct 21, 2025, 8:00 AM EDT - 5 weeks ago

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

Sep 23, 2025, 5:00 PM EDT - 2 months ago

Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Sep 11, 2025, 3:59 PM EDT - 2 months ago

CYBN Investors Have Opportunity to Join Cybin Inc. Fraud Investigation with the Schall Law Firm

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 11, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Sep 8, 2025, 7:30 AM EDT - 2 months ago

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 3 months ago

Cybin to Participate in the Cantor Global Healthcare Conference 2025

Cybin Announces Senior Leadership Changes

Sep 2, 2025, 7:30 AM EDT - 3 months ago

Cybin Announces Senior Leadership Changes

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 26, 2025, 7:30 AM EDT - 3 months ago

Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Announces Results of Annual Meeting of Shareholders

Aug 18, 2025, 5:30 PM EDT - 3 months ago

Cybin Announces Results of Annual Meeting of Shareholders

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Aug 13, 2025, 5:30 PM EDT - 3 months ago

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Aug 7, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:30 AM EDT - 4 months ago

Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jul 17, 2025, 7:30 AM EDT - 4 months ago

Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jul 1, 2025, 11:19 AM EDT - 5 months ago

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Jun 30, 2025, 10:03 PM EDT - 5 months ago

Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Jun 30, 2025, 9:27 PM EDT - 5 months ago

Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 13, 2025, 7:45 AM EDT - 6 months ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 12, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Jun 3, 2025, 7:30 AM EDT - 6 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 22, 2025, 7:30 AM EDT - 6 months ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 20, 2025, 7:30 AM EDT - 6 months ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 15, 2025, 7:30 AM EDT - 7 months ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 14, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 8, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin to Participate at the 28th Annual Milken Institute Global Conference

May 1, 2025, 7:30 AM EDT - 7 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 23, 2025, 7:30 AM EDT - 7 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Apr 21, 2025, 8:00 AM EDT - 7 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Feb 10, 2025, 9:48 PM EST - 10 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 15, 2025, 12:07 PM EST - 11 months ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 13, 2025, 7:30 AM EST - 11 months ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 9, 2025, 5:00 PM EST - 11 months ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 10, 2024, 7:30 AM EST - 1 year ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Dec 4, 2024, 7:30 AM EST - 1 year ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 18, 2024, 7:00 AM EST - 1 year ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 14, 2024, 7:30 AM EST - 1 year ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Nov 13, 2024, 7:30 AM EST - 1 year ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

BelieveinthePK
BelieveinthePK Nov. 29 at 4:00 PM
$CYBN Compass is going for a tx resistant depression indication whereas CYBN is pursuing a major depression indication (plus generalized anxiety reason for use with a non-psilocybin based molecule). CYBN has favorable pharmacokinetics because it uses deuterated psilocin which bypasses liver metabolism unlike compass’s psilocybin drug. VA probably chose Compass because of the indication and because they are a little further along with their phase 3 trial.
0 · Reply
Hanaleimike
Hanaleimike Nov. 28 at 8:07 PM
$CYBN so cybn vs compass. I’m invested in atai. I read today about the VA investment in a phase 3 with compass. Can someone explain the main differences between these two companies and why the VA would choose compass over cybin?
1 · Reply
Mastacash
Mastacash Nov. 27 at 5:08 PM
$CYBN I mean it would explain a lot with this stock, it has trading bizarre for 5 years. Get the f*ck of the neo exchange, what a cesspool Canada is. https://www.ctvnews.ca/business/article/market-manipulation-cases-trending-up-in-canada-regulator-data/
1 · Reply
outlawinvestor1
outlawinvestor1 Nov. 26 at 8:37 PM
$CYBN bought more today. updated outstanding shares after October financing ~50 million. company has ~$220M net cash after paying off debt. biotech funds bought for $6.50/sh. still a great deal below $6 imho. i assume price will start to rise as 2026 readouts approach.
0 · Reply
starbucks_cups_with_rum
starbucks_cups_with_rum Nov. 26 at 4:12 PM
$CYBN I will buy back in next year
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 26 at 2:19 AM
Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.15 - $0.25 Exit Price Target: $0.47 Profit Margin: +90% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
BankOnTheFuture
BankOnTheFuture Nov. 25 at 8:43 PM
$CMPS $ATAI $CYBN $MNMD
0 · Reply
CMontgomeryBurns
CMontgomeryBurns Nov. 25 at 8:36 PM
$CYBN NJ leading the way https://newjerseymonitor.com/2025/11/25/nj-bill-legalize-psychedelic-mushrooms/
0 · Reply
Rico_Again_Jorge
Rico_Again_Jorge Nov. 25 at 8:30 PM
$CYBN Do not try to be too smart in this place
0 · Reply
Rico_Again_Jorge
Rico_Again_Jorge Nov. 25 at 8:29 PM
$CYBN Just yourself
0 · Reply
IBSpazzin
IBSpazzin Nov. 25 at 8:27 PM
$CYBN Doug leaves around the time MindMed files for patents for psilocin. Now they have raised funds for R&D and acquisitions. New Jersey advances psilocybin bill.
0 · Reply
ChristopherMcC
ChristopherMcC Nov. 25 at 7:36 PM
$CYBN a Novo, Abbvie, etc sweats more cash into the ether on office supplies than it would cost to acquire Cybin at this valuation. That there isn't even a whiff is a major red flag. Will also be interesting to see how many shares P72 holds. My guess is 0.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 25 at 5:04 PM
💎 LiquidTheta® Live Actionable Trade Asset: $CYBN Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $1.26- $1.54 Scale out: $4.90-$8.40 Profit Potential : 408% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
BobJohnBuoy666
BobJohnBuoy666 Nov. 25 at 4:51 PM
$CYBN closed for 70% gain
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 25 at 2:20 AM
Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.25 - $0.25 Exit Price Target: $0.35 Profit Margin: +42% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Tradetime3472
Tradetime3472 Nov. 24 at 8:28 PM
$ATAI $CMPS $CYBN $MNMD and $PBM is the only Nasdaq listed company that has ibogaine operations straight from the source in Africa. Most likely will get a part of the $50M Texas ibogain fund
2 · Reply
Hardspot
Hardspot Nov. 24 at 5:48 PM
$CYBN sorry i forget, since they fired doug who is it we’re supposed to be mad at?
0 · Reply
stoxx0007
stoxx0007 Nov. 24 at 2:00 PM
$CYBN = where is everyone over here?
2 · Reply
PsychedStocks
PsychedStocks Nov. 24 at 8:25 AM
$CYBN $CMPS $MNMD $ATAI Connor McGregor just publically stated ibogaine treatment saved his life. There will be a whirlwind of coverage from other athletes and celebrities in the next year about life changing psychedelic experiences. Would not be surprised if they start publically backing companies in the sector
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 23 at 11:12 PM
💎 LiquidTheta® Live Actionable Trade Asset: $CYBN Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $1.12- $1.38 Scale out: $4.38-$7.50 Profit Potential : 262% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 23 at 3:42 AM
Hedge Alert Live - Protect Your Portfolio Contract: $CYBN $5.00 Put · DEC 19, 2025 Exp Entry Price: $0.28 - $0.30 Exit Price Target: $0.43 Profit Margin: +54% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 22 at 2:26 PM
💎 LiquidTheta® Live Actionable Trade Asset: $CYBN Contracts: $CYBN May 15, 2026 $8 Calls Scale in: $1.52- $1.86 Scale out: $5.91-$10.12 Profit Potential : 64% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply